The history of a transdermal product: From innovation to generic

[Display omitted] The development, registration and successful launch of a novel, innovative transdermal pharmaceutical product requires an idea, structured planning and a highly skilled, specialist team. It is not often that the opportunity arises to document this activity. This paper demonstrates...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2022-05, Vol.619, p.121692-121692, Article 121692
Main Authors: Watkinson, A.C., Colagrande, F.
Format: Article
Language:English
Subjects:
Administration, Cutaneous
Axiron
Drug development
Drug Industry
Drugs, Generic
Humans
Testosterone
Transdermal delivery
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c243t-12bece07b636347e86f580005cad87ce43bafc255a523d6d0e5724bfb1501fd33
container_end_page 121692
container_issue
container_start_page 121692
container_title International journal of pharmaceutics
container_volume 619
creator Watkinson, A.C.
Colagrande, F.
description [Display omitted] The development, registration and successful launch of a novel, innovative transdermal pharmaceutical product requires an idea, structured planning and a highly skilled, specialist team. It is not often that the opportunity arises to document this activity. This paper demonstrates the multidisciplinary effort required to take such a product (Axiron®, a transdermal testosterone product) from innovation to market and also describes its ultimate fate after the generic drug industry took an interest in its commercial success. Although many understand various aspects of this drug development process this understanding is often, by necessity, limited to the specialities of each of the individuals involved. It is hoped that this paper will provide an interesting overview of the entire process from beginning (innovation) to end (genericization).
doi_str_mv 10.1016/j.ijpharm.2022.121692
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2644013484</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517322002472</els_id><sourcerecordid>2644013484</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-12bece07b636347e86f580005cad87ce43bafc255a523d6d0e5724bfb1501fd33</originalsourceid><addsrcrecordid>eNqFkD1PwzAQhi0EoqXwE0AeWVL8ETuBBVBFAakSS5ktx75QR0lc7KRS_z2pUliZbnnu3vcehK4pmVNC5V01d9V2o0MzZ4SxOWVU3rMTNKV5xhOeZvIUTQnP8kTQjE_QRYwVIUQyys_RhAvOac7pFD2tN4A3LnY-7LEvscZd0G20EBpd423wtjfdA14G32DXtn6nO-db3Hn8BS0EZy7RWanrCFfHOUOfy5f14i1Zfby-L55XiWEp7xLKCjBAskJyObSDXJYiHwoJo22eGUh5oUvDhNCCcSstAZGxtCgLKggtLeczdDveHTp99xA71bhooK51C76Pisk0JZSneTqgYkRN8DEGKNU2uEaHvaJEHeSpSh3lqYM8Ncob9m6OEX3RgP3b-rU1AI8jAMOjOwdBReOgNWBdANMp690_ET8-qYIq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2644013484</pqid></control><display><type>article</type><title>The history of a transdermal product: From innovation to generic</title><source>ScienceDirect Freedom Collection</source><creator>Watkinson, A.C. ; Colagrande, F.</creator><creatorcontrib>Watkinson, A.C. ; Colagrande, F.</creatorcontrib><description>[Display omitted] The development, registration and successful launch of a novel, innovative transdermal pharmaceutical product requires an idea, structured planning and a highly skilled, specialist team. It is not often that the opportunity arises to document this activity. This paper demonstrates the multidisciplinary effort required to take such a product (Axiron®, a transdermal testosterone product) from innovation to market and also describes its ultimate fate after the generic drug industry took an interest in its commercial success. Although many understand various aspects of this drug development process this understanding is often, by necessity, limited to the specialities of each of the individuals involved. It is hoped that this paper will provide an interesting overview of the entire process from beginning (innovation) to end (genericization).</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2022.121692</identifier><identifier>PMID: 35331831</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Cutaneous ; Axiron ; Drug development ; Drug Industry ; Drugs, Generic ; Humans ; Testosterone ; Transdermal delivery</subject><ispartof>International journal of pharmaceutics, 2022-05, Vol.619, p.121692-121692, Article 121692</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c243t-12bece07b636347e86f580005cad87ce43bafc255a523d6d0e5724bfb1501fd33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35331831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Watkinson, A.C.</creatorcontrib><creatorcontrib>Colagrande, F.</creatorcontrib><title>The history of a transdermal product: From innovation to generic</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted] The development, registration and successful launch of a novel, innovative transdermal pharmaceutical product requires an idea, structured planning and a highly skilled, specialist team. It is not often that the opportunity arises to document this activity. This paper demonstrates the multidisciplinary effort required to take such a product (Axiron®, a transdermal testosterone product) from innovation to market and also describes its ultimate fate after the generic drug industry took an interest in its commercial success. Although many understand various aspects of this drug development process this understanding is often, by necessity, limited to the specialities of each of the individuals involved. It is hoped that this paper will provide an interesting overview of the entire process from beginning (innovation) to end (genericization).</description><subject>Administration, Cutaneous</subject><subject>Axiron</subject><subject>Drug development</subject><subject>Drug Industry</subject><subject>Drugs, Generic</subject><subject>Humans</subject><subject>Testosterone</subject><subject>Transdermal delivery</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkD1PwzAQhi0EoqXwE0AeWVL8ETuBBVBFAakSS5ktx75QR0lc7KRS_z2pUliZbnnu3vcehK4pmVNC5V01d9V2o0MzZ4SxOWVU3rMTNKV5xhOeZvIUTQnP8kTQjE_QRYwVIUQyys_RhAvOac7pFD2tN4A3LnY-7LEvscZd0G20EBpd423wtjfdA14G32DXtn6nO-db3Hn8BS0EZy7RWanrCFfHOUOfy5f14i1Zfby-L55XiWEp7xLKCjBAskJyObSDXJYiHwoJo22eGUh5oUvDhNCCcSstAZGxtCgLKggtLeczdDveHTp99xA71bhooK51C76Pisk0JZSneTqgYkRN8DEGKNU2uEaHvaJEHeSpSh3lqYM8Ncob9m6OEX3RgP3b-rU1AI8jAMOjOwdBReOgNWBdANMp690_ET8-qYIq</recordid><startdate>20220510</startdate><enddate>20220510</enddate><creator>Watkinson, A.C.</creator><creator>Colagrande, F.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220510</creationdate><title>The history of a transdermal product: From innovation to generic</title><author>Watkinson, A.C. ; Colagrande, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-12bece07b636347e86f580005cad87ce43bafc255a523d6d0e5724bfb1501fd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Administration, Cutaneous</topic><topic>Axiron</topic><topic>Drug development</topic><topic>Drug Industry</topic><topic>Drugs, Generic</topic><topic>Humans</topic><topic>Testosterone</topic><topic>Transdermal delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Watkinson, A.C.</creatorcontrib><creatorcontrib>Colagrande, F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Watkinson, A.C.</au><au>Colagrande, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The history of a transdermal product: From innovation to generic</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2022-05-10</date><risdate>2022</risdate><volume>619</volume><spage>121692</spage><epage>121692</epage><pages>121692-121692</pages><artnum>121692</artnum><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted] The development, registration and successful launch of a novel, innovative transdermal pharmaceutical product requires an idea, structured planning and a highly skilled, specialist team. It is not often that the opportunity arises to document this activity. This paper demonstrates the multidisciplinary effort required to take such a product (Axiron®, a transdermal testosterone product) from innovation to market and also describes its ultimate fate after the generic drug industry took an interest in its commercial success. Although many understand various aspects of this drug development process this understanding is often, by necessity, limited to the specialities of each of the individuals involved. It is hoped that this paper will provide an interesting overview of the entire process from beginning (innovation) to end (genericization).</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35331831</pmid><doi>10.1016/j.ijpharm.2022.121692</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2022-05, Vol.619, p.121692-121692, Article 121692
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_2644013484
source ScienceDirect Freedom Collection
subjects Administration, Cutaneous
Axiron
Drug development
Drug Industry
Drugs, Generic
Humans
Testosterone
Transdermal delivery
title The history of a transdermal product: From innovation to generic
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A29%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20history%20of%20a%20transdermal%20product:%20From%20innovation%20to%20generic&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Watkinson,%20A.C.&rft.date=2022-05-10&rft.volume=619&rft.spage=121692&rft.epage=121692&rft.pages=121692-121692&rft.artnum=121692&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2022.121692&rft_dat=%3Cproquest_cross%3E2644013484%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c243t-12bece07b636347e86f580005cad87ce43bafc255a523d6d0e5724bfb1501fd33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2644013484&rft_id=info:pmid/35331831&rfr_iscdi=true